Multiple Cutaneous and Uterine Leiomyomas: Refinement of the Genetic Locus for Multiple Cutaneous and Uterine Leiomyomas on Chromosome 1q42.3–43 by Martínez Mir, Amalia et al.
Multiple Cutaneous and Uterine Leiomyomas: Refinement of the Genetic Locus 
for Multiple Cutaneous and Uterine Leiomyomas on Chromosome 1q42.3–43 
Amalia Martinez-Mir*, Derek Gordon‡, Liran Horev§, Laurent Klapholz§, Jurg Ott‡, Angela 
M Christiano*,† and Abraham Zlotogorski§ 
 
*Department of Dermatology, Columbia University, New York, New York, U.S.A. 
†Department of Genetics and Development, Columbia University, New York, New York, 
U.S.A. 
‡Laboratory of Statistical Genetics, Rockefeller University, New York, New York, U.S.A. 
§Department of Dermatology, Hadassah University Medical Center, Jerusalem, Israel 
 
Correspondence: Dr Abraham Zlotogorski, Department of Dermatology, Hadassah University 




Cutaneous leiomyomas, rare benign tumors originating from the arrector pili muscle of the hair 
follicle, can be associated with the common uterine fibroids in a syndrome called multiple 
cutaneous and uterine leiomyomas. Multiple cutaneous and uterine leiomyomas are inherited as an 
autosomal dominant trait, providing an excellent opportunity for the study of the common non-
Mendelian manifestation of isolated uterine fibroids. This study reports the clinical and molecular 
characterization of an extended family with multiple cutaneous and uterine leiomyomas. Linkage 
analysis has shown that the disease in this family is linked to the recently reported genetic locus for 
multiple cutaneous and uterine leiomyomas, with a maximum two-point LOD score of 4.453 for 
markers D1S2670, D1S2785, D1S547, and D1S1609. The identification of key recombination 
events has allowed us to refine substantially the location of the genetic locus for multiple cutaneous 
and uterine leiomyomas, from 14 cM to an interval of 4.55 or 7.19 cM, depending on the final 
phenotype of a young family member in which one of the key recombination events has occurred. 
In addition, we provide a description of the interesting pattern and progression of the skin 
phenotype in this four-generation kindred. The refinement of the genetic locus for multiple 
cutaneous and uterine leiomyomas and the availability of an extended multigeneration pedigree will 
facilitate the identification of the mutated gene responsible for multiple cutaneous and uterine 
leiomyomas, which, in turn, may provide key information for the understanding of the molecular 
basis of the common uterine fibroids. 
Keywords: genetic locus for multiple cutaneous and uterine leiomyomas, leiomyoma 
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Cutaneous leiomyomas are benign tumors arising from the arrector pili muscle of the hair follicle. 
They can range in number from a few to several hundred. Skin leiomyomas are found in association 
with uterine leiomyomas in an autosomal dominant syndrome called multiple cutaneous and uterine 
leiomyomas (MCL; MIM 150800) (Reed et al, 1973;Thyresson and Su, 1981;Valdivia et al, 
1983;Garcia Muret et al, 1988;Fernandez-Pugnaire and Delgado-Florencio, 1995;Fearfield et al, 
2000;Konig and Happle, 2000;Alam et al, 2001). One of the main approaches for the elucidation of 
the genetic components underlying a complex trait is the study of related Mendelian disorders. Such 
is the case for the common uterine leiomyomas (myomas or fibroids), where both genetic and 
nongenetic factors are thought to play a part, and MCL, a Mendelian disease. 
Very recently, the locus responsible for MCL has been mapped to an  14 cM region on 
chromosome 1q42.3–43 (Alam et al, 2001). Moreover, the same locus has been identified in a 
separate study as the susceptibility locus for a hereditary cancer syndrome, including renal cell 
cancer, as well as uterine and cutaneous leiomyomas (Kiuru et al, 2001;Launonen et al, 2001). This 
study reports the clinical and genetic findings in an extended pedigree with MCL. The clinical 
features of MCL in a new large family are described in detail, with emphasis on the particular 
timing of the appearance and progression of the skin lesions. Moreover, evidence is provided for a 
case of type II segmental manifestation of cutaneous leiomyoma within the family. The genetic 
analysis of this pedigree has allowed us to narrow the location of the genetic locus for multiple 
cutaneous and uterine leiomyomas (MCUL1) to a region of 4.55–7.19 cM on chromosome 1. 
Materials and methods 
Patients 
Forty-three family members of a large Israeli family with MCL were interviewed and examined by 
two physicians. Photographs were taken during these meetings and blood samples collected 
following informed consent. Four family members, II-3, III-8, III-9, and IV-14 (Figure 1), were 
available only for the interview and examination and one member (II-1) only for blood collection. 
Skin and uterine involvement of the offspring of II-1 was reported anecdotally by relatives. 
Biopsies taken prior to this study from four affected patients confirmed the diagnosis of cutaneous 
(III-17, III-19, III-21, and IV-5) and uterine (III-17, III-19) leiomyomas. 
Linkage analysis 
Blood samples were collected from 40 family members and genomic DNA was extracted using the 
PureGene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). Two genomic regions were 
analyzed before embarking in a genome-wide scan: chromosome 18p, as monosomy for this 
chromosomal region has been described in a patient with mental retardation and multiple cutaneous 
leiomyomas, and the MCUL1 locus, on chromosome 1q. Microsatellite markers covering these 
regions were chosen from the genetic map at the Center for Medical Genetics, Marshfield Medical 
Research Foundation (Broman et al, 1998), and the sequences for their polymerase chain reaction 
(PCR) primers obtained from the Genome Database and the Cooperative Human Linkage Center. 
The (PCR) amplification products were resolved on 6% nondenaturing polyacrylamide gels and 
visualized by ethidium bromide staining. 
Two-point, multipoint, and haplotype analyses were performed on the pedigree. For all linkage 
analyses, a dominant model with age-dependent penetrance was assumed. Seven liability classes 
were defined as follows: age 0–10, 0.001; age 11–20, 0.500; age 21–30, 0.700; age 31–40, 0.800; 
41–50, 0.900; 51–60, 0.950; 61 or older, 1.000. The disease allele was assumed to have a frequency 
of 0.001. The marker-allele frequencies were estimated from the data using observed and 
reconstructed genotypes of founders within the pedigrees. To avoid computation errors due to 
observed allele frequencies of 0.0, marker alleles for all markers were re-coded using the RECODE 
program (Weeks, 2000). This re-coding program insured that alleles were numbered sequentially, 
and that every allele frequency was nonzero. In addition, the re-coding had no effect on any of the 
analyses, in terms of power of the methods. 
Two-point analyses were carried out using the MLINK program of the FASTLINK suite of 
programs (Lathrop et al, 1984;Cottingham et al, 1993;Schaffer et al, 1994). LOD scores were 
computed for  (recombination fraction) values ranging over the interval (0.0, 0.5) in increments of 
0.02, as well as  = 0.05. In the interest of brevity, only a small number of LOD score values for 
each marker locus are reported (Table I). 
Multipoint and haplotype analyses were carried out using the SIMWALK program version 2.8 
(Sobel and Lange, 1996). This software was chosen because it employs a Markov chain Monte 
Carlo approach, which allows for both a large number of founders in a pedigree and multiple 
markers in the computation of LOD scores. Markers were chosen for the multipoint analysis 
according to the following steps: (i) all markers that showed 0.0 recombination fractions with other 
markers according to the Marshfield genetic map (Broman et al, 1998) were put into distinct 
groups, and (ii) among markers in the distinct groups, those markers with the largest heterozygosity 
were chosen for multipoint analysis. This procedure was followed as the method used in 
SIMWALK has computational limitations for markers with 0.0 recombination distances (E. Sobel, 
personal communication). As a result of this procedure, two markers, D1S2670 and D1S547, were 
excluded from the multipoint and haplotype analyses. Recombination distances between markers 
were computed using the sex-averaged Marshfield genetic map (Broman et al, 1998). For haplotype 
analysis, we used the same set of markers as those used for multipoint analysis. Informative 
recombination events are discussed in Results. 
Family members with cutaneous leiomyomas were classified as affected. All individuals younger 
than the age of onset of their affected parent were scored as unknown. Finally, although II-1 and II-
5 had affected offspring, they were also classified as unknown, as they were not examined by the 
authors and clinical records on the skin involvement were not available. 
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Ensembl Genome Server, http://www.usensembl.org 
GeneMap'99, http://www.ncbi.nlm.nih.gov/genemap99/ 
Genome Database, The, http://www.gdb.org 
Human Genome Project Working Draft, http://www.genome.ucsc.edu/index.html 
National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov 
Results 
Clinical findings 
The individuals in this study belong to a four-generation pedigree from Israel in which MCL is 
inherited in an autosomal dominant manner (Figure 1). All patients reported sensitivity to touch, 
and pain to cold exposure. Skin leiomyomas were found in 10 individuals (six females and four 
males), ranging in age from 18 to 65. In two additional family members, a history of skin 
leiomyoma was reported by their relatives. In six of 10 patients, the disease started at age 18–20, 
whereas the rest developed the disease at age 14 (V-12), 30 (IV-2), 45 (III-19), and 55 (III-21). The 
lesions were firm, skin colored to pinkish-red, ranged in number from few in the younger members 
to up to 100 in the oldest individual examined (III-17), and their diameter ranged from 0.2 cm to 
1.0 cm (Figure 2). The number of lesions increased with time and became more grouped. The 
pattern of progression was highly consistent among the patients. In six affected members, the 
disease started on the left arm, where only two or three leiomyomas were found (Figure 2a). In two 
other members, two or three lesions first appeared on the left anteromedial thigh and then on the left 
arm. Following the left arm, a few lesions appeared on the left upper back in nine of 10 patients, 
and then on the right upper back in five patients (Figure 2b), the right lower back (Figure 2c), right 
arm, and right leg. The involvement of the right side in patients who had a more prolonged disease 
(III-17, III-19, III-21, IV-3, and IV-5) was more severe than on the left side. Patient IV-13, aged 
26 y, showed only involvement of the right arm (one lesion) and the lower right abdomen (one 
lesion). Interestingly, the major exception was V-12, a young female aged 18. She first developed 
the disease at an early age, 14 y old, with multiple painful, firm, pale red skin lesions, of 
approximately 0.2–0.5 cm in size, on the right shin followed by the right lower thigh. On 
examination, at age 18, two pale painful lesions were also found on the left upper arm and two on 
the left upper back in accordance with the typical pattern observed in other family members. 
Regarding the uterine involvement, two affected females, III-17 and III-19, underwent 
hysterectomy due to uterine myomas at ages 38 and 30, respectively. Individual IV-12 has myomas. 
Among the rest of the affected females, II-5 suffered from abdominal pains and died during labor 
due to suspected uterine tumor at age 34, and V-12 suffered from menometrorrhagia. Individuals 
III-21 and IV-2 denied having myomas or related symptoms. Finally, III-9, the daughter of an 
unaffected mother, had a hysterectomy at age 28. This case would be in accordance with the high 
prevalence of uterine leiomyoma among women (Stewart, 2001). No other diseases were reported 
in the family, except for patient III-17 who suffered from an undiagnosed progressive neurologic 
disease. 
Confirmation and refinement of the MCUL1 locus 
As an initial step, prior to performing a genome-wide scan, we analyzed the candidate loci on 
chromosomes 18p and 1q42.3–43 (MCUL1). As monosomy for 18p had been described in a patient 
with mental retardation and cutaneous leiomyoma (Fryns et al, 1985), we performed a cytogenetic 
analysis in one of the patients, III-21, and no chromosomal alterations were found. To definitively 
rule out this chromosomal region we performed cosegregation analysis with microsatellite markers 
covering chromosome 18p and found no evidence of linkage (data not shown). These results are not 
unexpected, asTurleau et al (1988) also excluded cytogenetic abnormalities in three cases of MCL. 
Analysis of the MCUL1 locus, on the other hand, provided strong evidence in favor of linkage. To 
confirm these results, we typed a total of 12 markers in the region. A maximum two-point LOD 
score of 4.453 was obtained for markers D1S2670, D1S2785, D1S547, and D1S1609 (  = 0) (Table 
I). Multipoint analysis supported linkage to this region, with a maximum multipoint LOD score of 
4.453 throughout the interval D1S2785–D1S1609. Haplotype analysis revealed critical 
recombination events in two family members, III-17 and V-2 (Figure 1). In III-17, an affected 
female, a recombination event has occurred between markers D1S517 and D1S2670. This 
recombination event identifies the same centromeric boundary as the one established in previous 
reports (Alam et al, 2001;Launonen et al, 2001); however, individual V-2, an unaffected 19 y old 
female, provides key information to narrow the MCUL1 locus. As V-2 is too young, we need to 
consider two alternatives. If V-2 does carry the disease gene, the recombination event would narrow 
the MCUL1 locus from 14 cM (Alam et al, 2001), to a 7.19 cM interval, between markers D1S2785 
(recombination in individual V-2, this study) and D1S2842 (individual 302, from family ML304, 
inAlam et al, 2001). If, on the contrary, V-2 does not carry the disease gene, we would have 
narrowed the disease locus to a 4.55 cM interval, flanked by markers D1S517 (recombination in 
individual III-17, this study) and D1S204 (V-II). 
Discussion 
The identification of the MCUL1 locus as responsible for the disease in the pedigree studied here, 
one of the largest MCL kindreds reported up to now, provides strong evidence for the genetic nature 
of the disease, inherited as an autosomal dominant trait. 
Both the age of onset and the pattern of clinical symptoms appear to be consistent throughout the 
pedigree. Seven of 10 affected individuals developed the disease before age 20. Two patients 
claimed that the disease started at ages 45 (III-19) and 55 (III-21); however, the location of the first 
skin lesions in most of the family members (see clinical findings in Results) raises the possibility 
that the first lesions could go unnoticed by some patients. It is of interest that patient III-19 was 
diagnosed to have uterine myoma since at least age 30. This patient has eight unaffected children, 
aged 24–42. As this is an extremely rare situation, with a probability of 0.4%, the eight siblings 
were examined by two dermatologists and none was found to be affected. Furthermore, all five 
daughters denied any history of abdominal pain, irregular bleeding, or an enlarged uterus. 
The striking finding in this family is the relatively constant pattern of progression of the skin 
lesions, from left to right, which does not fit any known skin patterning lines, such as Blashko's 
lines (Happle, 1993). To our knowledge, this phenomenon was not noticed previously, although the 
increased number of lesions with time has been documented in some studies. Skin leiomyomas have 
been classified so far as solitary, segmental, dermatomal, or disseminated; however, it is possible 
that this classification could be based on incomplete clinical observations. Patient V-12 is an 
interesting case, as she may represent an example of type II segmental leiomyomatosis (localized 
loss of heterozygosity or LOH) superimposed upon familial disseminated cutaneous 
leiomyomatosis. Previous reports have documented the earlier appearance of segmental lesions in 
cutaneous leiomyoma (Happle, 1997). According toHapple (1993), when disseminated and 
segmental leiomyomatosis coexist, "the lesions in the segmental pattern tend to be more numerous 
and prominent than the other tumors present in the same patient and his family members". These 
observations would explain both the early onset of the first skin lesions in V-12, at age 14, and the 
more severe manifestation observed in the segmental involvement, compared with the rest of the 
affected family members. 
Of special interest is that pedigrees such as those reported byAlam et al(2001),Launonen et 
al (2001), and this study, can provide insights into more complex diseases, such as common uterine 
leiomyomas, where a genetic predisposition is only suspected. The susceptibility to uterine myomas 
is thought to have environmental, hormonal, and genetic components (Stewart, 2001). In MCL, 
however, uterine leiomyomas are clearly inherited in an autosomal dominant fashion, with 
incomplete penetrance in some pedigrees (Thyresson and Su, 1981;Valdivia et al, 1983;Garcia 
Muret et al, 1988;Fernandez-Pugnaire and Delgado-Florencio, 1995;Fearfield et al, 2000;Konig and 
Happle, 2000;Alam et al, 2001). Both cutaneous and uterine leiomyomas have been associated with 
several chromosomal abnormalities. A patient with severe mental retardation and multiple 
cutaneous leiomyomas has been described with 9p trisomy/18p monosomy (Fryns et al, 1985). 
Moreover, about 40–50% of uterine leiomyomas are associated with chromosomal abnormalities in 
the tumors, with chromosomes 6, 7, 12, and 14 as the most frequently involved (seeLigon and 
Morton, 2001, for a review). In addition, deletion of both COL4A5 andCOL4A6 genes on the X 
chromosome have been identified in esophageal leiomyomatosis associated with Alport syndrome 
(Heidet et al, 1995;Ueki et al, 1998). 
The most compelling evidence for a genetic basis of leiomyoma, however, is the recent 
identification of the MCUL1 locus on chromosome 1q42.3–43, in a group of 10 families with 
multiple cutaneous leiomyomas and uterine fibroids (Alam et al, 2001) and the identification of two 
pedigrees with the specific combination of renal cell cancer and uterine and cutaneous leiomyomas 
linked to the same locus (Kiuruet al, 2001; Launonen et al, 2001). In both studies, LOH at the 
linked locus has been found in some of the tumors, suggesting the possibility of an underlying 
tumor suppressor gene. 
In the report by Alam et al (2001) one of 11 families with MCL was not linked to theMCUL1 locus. 
Although the possibility remains that the genetic susceptibility to MCL is genetically 
heterogeneous, the authors point to phenocopies or a diagnostic error in the unlinked family as 
alternative explanations. Moreover, both pedigrees studied by Launonen et al (2001), with the 
combination of MCL and renal cancer are also linked to MCUL1. Assuming genetic homogeneity, 
our results significantly refine the MCUL1 locus. As the key recombination event has taken place in 
a young unaffected female, V-2, we must consider two possible scenarios based on her definitive 
phenotype: the refinement of the MCUL1 locus to a 7.19 cM interval, if V-2 does, indeed, carry the 
mutated gene; or a considerably shorter interval of 4.55 cM if V-2 does not carry a 
mutated MCUL1 allele. Although careful repeated clinical examination of V-2 did not reveal any 
sign of the disease, she is still too young to draw any conclusion. Her affected mother and brother 
developed the disease at ages 30 and 18, respectively. The age of onset in the family studied ranged 
from 14 to 55; however, six of 10 family members developed the disease before age 18, and seven 
of 10 before age 20. 
Ten of the 14 individuals carrying the disease-associated haplotype were already affected at the 
time of the study (Figure 1). Two of the remaining individuals with this haplotype (II-1 and II-5) 
were scored as unknown for linkage analysis purposes even though they had affected offspring, 
because they were not examined. Moreover, II-5 suffered from abdominal pains and died from a 
suspected uterine tumor during labor, at age 34. Finally, V-2 and V-17 are 19 and 18 y old, 
respectively, thus they are still too young to draw any definitive conclusion. The rest of family 
members classified as unknown (IV-15 through IV-21), ranging in age from 24 to 42 y old and 
coded as unknown because their mother developed the cutaneous disease at age 45, as well as the 
children in the last generation, all under age 21, have inherited the wild-type chromosome from 
their affected parent (Figure 1). 
The data presented in this study show that MCUL1 is inherited as an autosomal dominant gene with 
high penetrance, in accordance withAlam et al (2001). In their pedigrees, seven unaffected 
individuals, aged 28–67, carry the disease-associated haplotype. The results reported byLaunonen et 
al (2001), on the other hand, show a more complex scenario. Although they have identified one 
single unaffected carrier (unspecified age), only 14 of 16, seven of 16, and six of 16 carriers have 
developed uterine leiomyoma/leiomyosarcoma, cutaneous leiomyomas, and renal cell cancer, 
respectively. 
The MCUL1 interval includes several known genes, as well as many unknown expressed sequence 
tags, although there is no obvious candidate among them (Human Genome Project Working Draft; 
National Center for Biotechnology Information; Ensembl Genome Server; GeneMap'99). The 
further refinement of the critical linkage interval will be needed to define the exact location of 
the MCUL1locus, as well as to elucidate the possibility of heterogeneity on the genetic 
predisposition to MCL. It is of interest that both LOH (Mao et al, 1999) and balanced translocations 
(Mitelman et al, 1997) have been reported in uterine leiomyomas involving the chromosomal region 
1q42. 
The recent reports on the identification of the MCUL1 locus, together with the data presented here 
may provide valuable insights into the etiology and genetic causes of skin and uterine leiomyomas, 
the latter being a major health issue for women. Its association with the more aggressive renal cell 
cancer (Kiuru et al, 2001; Launonen et al, 2001) may facilitate early patient identification. Finally, 
the development of new drugs and treatments may be achieved once the molecular basis of these 
tumors is established. 
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Figures 
Figure I 
 Pedigree with MCL, showing the haplotypes for markers at 1q42.3–43. Black, gray, and empty 
symbols indicate family members scored as affected, unknown, and unaffected in the linkage 
analysis, respectively. The order of the markers is indicated in the upper right corner. The disease-
associated haplotype is boxed. Genotypes in parentheses for family members II-5 and III-18 were 
inferred from their offspring. The genotype for marker GGAA27E08 in individual V-4 could 




Clinical findings in the MCL pedigree. In most family members, the disease begins with 
leiomyomas on the left upper arm (patient IV-3:a).The disease then progresses to the left upper back 
and right upper back (patient III-17: b), and then to the middle and lower right back (patient III-
17: c). 
Tables 
Table I. Two-point LOD scores for chromosome 1q42.3–43 markers in the MCL pedigree 
    LOD score at  = 
Marker Genetic location (cM) 0.00 0.01 0.05 0.1 0.2 0.3 0.4 
D1S517 262.96 - 17.24 2.38 2.80 2.73 2.26 1.61 0.85 
D1S2670 262.96 4.45 4.38 4.07 3.68 2.83 1.91 0.94 
D1S2785 266.27 4.45 4.38 4.07 3.68 2.83 1.91 0.94 
D1S204 267.51 1.64 1.60 1.43 1.20 0.77 0.39 0.12 
D1S547 267.51 4.45 4.38 4.07 3.68 2.83 1.91 0.94 
GGAA27E08 272.27 0.47 0.47 0.45 0.43 0.37 0.27 0.15 
D1S1609 274.53 4.45 4.38 4.07 3.68 2.83 1.91 0.94 
 
